Sales & Marketing One year later, EVERSANA plans to go beyond the AI agency At an event in New York City, EVERSANA shared updates, customer perspectives, and future plans for its AI agency, which is moving beyond that mandate.
News Lundbeck taps EVERSANA’s AI Agency for commercialisation In advance of its NYC event, EVERSANA announces expanded AI agency capabilities and a partnership with brain health giant Lundbeck.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
News Tarek Samad takes on task of delivering on Lundbeck's R&D Lundbeck names Tarek Samad to replace its retiring R&D chief, Johan Luthman, and he is facing a tough task as the firm heads towards a patent cliff.
News Key pipeline drug for Lundbeck delivers in Cushing syndrome Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.
News Axsome breaks new ground in Alzheimer's with Auvelity OK Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.